Trial Profile
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 914
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 22 Mar 2024 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 12 Feb 2024 Status changed from active, no longer recruiting to completed.